For years, the de minimis loophole has flooded the U.S. with uninspected, untaxed, and often dangerous goods—from counterfeit products to fentanyl precursors fueling America’s opioid crisis.
Tariffs are an effective tool for boosting domestic production. They stimulate critical domestic investment and increase U.S. manufacturing capacity. It’s past time to abandon the outdated dogma of unregulated free trade — and start focusing on rebuilding American industry to create jobs and ensure long-term economic resilience.
Nine different companies joined members of the House Select Committee on China at a press conference on Wednesday to talk about their battles with “China trade cheats” that have cost them a fortune. Most of them closed factories, or rolled back investment. Despite tariffs and anti-dumping (AD/CVD) trade case victories, the battle continues.
CPA’s report demonstrates that previous tariff exemptions and exclusions significantly weakened the effectiveness of the original tariffs imposed in 2018.
In 2024, China and India accounted for 57.6% of total U.S. pharmaceutical imports by weight, highlighting the potential risks associated with such reliance. Growing U.S. dependence on China and India for widely-used generic pharmaceutical products creates serious risks to national security and patient safety when drugs are in short supply, or ineffective.
President Trump’s executive order sends a clear message: The days of allowing China to weaponize US investment and financial markets against us are over.
Howard Lutnick understands that America’s trade policies must put U.S. producers, workers, and national security first. His leadership at the Commerce Department will be crucial in ensuring President Trump’s America First Trade Policy is fully implemented.
CPA announced key leadership changes as CEO Michael Stumo steps down to take on a new role in the Trump administration. Jon Toomey has been elevated as President of CPA to lead the organization and Nick Iacovella has been promoted to Executive Vice President.
For far too long, America has been at the mercy of foreign producers that routinely violate FDA safety regulations for life-saving medicines, generic drugs, and essential medical equipment.
This long-overdue action will protect American manufacturers and workers from the devastating surge of foreign imports that has harmed U.S. industry, particularly from Mexico in blatant violation of the 2019 Joint Steel and Aluminum Agreement.
